European Life Technologies has officially introduced itself to the Asian market, where our developments in bioinformatics and liquid biopsy have already generated strong professional interest. Our delegation participated in high-level ministerial meetings, engaging in successful discussions with key strategic partners.
Cancer is a complex multi-factorial disease that results from many molecular alterations. Among the observed effects are alterations in proliferation, growth, replication, and death of cells. Global genomic analyses coupled to functional assays have shown that altered gene expression is one possible mechanism of disease development. In human cells, genes are decoded in immature messages, which must be processed to generate functional proteins.
Messenger RNA Vaccines: Beckoning of a New Era in Cancer Immunotherapy
Messenger RNA (mRNA) vaccines are a relatively new class of vaccines. They combine the potential of mRNA to encode for almost any protein with an excellent safety profile and a flexible production process. During the last decade, the mRNA vaccine approach has been increasingly recognized and viewed as a versatile tool for the development of new innovative therapeutics not only in infectious disease settings but also in cancer. mRNA vaccines traditionally consist of a messenger RNA synthesized by in vitro transcription using a bacteriophage RNA polymerase and a template DNA that encodes the antigen(s) of interest.
